In addition, clinical samples were used to detect the expression of BYSL in non-tumor brain tissues and GBM tissues, and to explore the correlation between BYSL and mesenchymal makers (e.g., CHI3L1 and CD44). This evidence concerns the gene CHI3L1 and glioblastoma.